ArticleBreast cancer research : BCR2026
Development and validation of an immune-related molecular subtyping model based on a four-gene prognostic biomarker signature and multi-omics integrative analysis in Luminal B breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLuminal B breast cancer (LBBC) is characterized by marked molecular heterogeneity and unfavorable therapeutic outcomes, underscoring the need for concise and biologically interpretable biomarkers that can support reliable prognostic stratification. However, existing biomarker signatures are often redundant, weakly generalizable, and insufficiently validated in multi-omics regulatory consistency.
methodsUsing a minimum prognostic-redundancy feature identification strategy, we identified an immune-related four-gene prognostic biomarker signature and determined its optimal classification scheme. A molecular subtyping model was subsequently developed and externally validated to distinguish two prognostic immune subtypes: the immune-barren type (IBT) and the immune-enriched type (IET). Functional enrichment analysis, tumor immune microenvironment profiling, and multi-omics integrative consistency assessments were performed to elucidate the biological characteristics and regulatory underpinnings of the predicted subtypes. Moreover, the clinical independence, prognostic robustness, and cross-cohort reproducibility of the model were comprehensively evaluated, and independent clinical variables were incorporated to construct an individualized decision-support tool.
resultsThe four-gene biomarker signature demonstrated strong prognostic discrimination and subtype classification capability (max AUC = 0.86, P < 0.05). Across extensive multi-source external cohorts (n = 1,841), the molecular subtyping model robustly stratified patients into immune-related subtypes with significantly different survival outcomes and consistently high predictive performance (ACC ≥ 0.93, AUC ≥ 0.97, all P < 0.001), while remaining independent of conventional clinical variables (P < 0.001). Furthermore, the predicted subtypes exhibited concordant immune functional characteristics and multi-omics regulatory consistency (all P < 0.05). In addition, the individualized decision-support tool showed significant prognostic relevance (P = 0.004) and favorable comparative performance relative to previously reported prognostic models (AUC = 0.86).
conclusionThis immune-related molecular subtyping model, derived from a four-gene prognostic biomarker signature and supported by multi-omics integrative evidence, provides a robust and clinically independent model for prognostic stratification in LBBC. These findings offer a biologically interpretable basis for individualized risk assessment and may facilitate precision-oriented clinical decision support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.